Skip to main content

View full-text article in PMC

. 2011 Mar 1;11(3):163–172.

Table 1. Descriptive baseline characteristics of the subjects included in this study.

Study	Sample size	Race	Genotype	Drug	Therapy time	Follow-up time	Efficacy measures
Ge D, et al. (2009)	1137	946 (Caucasians)	1137 (1)	PEG-IFN-α-2a or -2b/RBV	48 wk	24w	SVR, non-SVR
Ge D, et al. (2009)	1137	191 (Afro-Americans)	1137 (1)	PEG-IFN-α-2a or -2b/RBV	48 wk	24w	SVR, non-SVR
Suppiah V, et al . (2009)	848	848 (Caucasians)	848 (1)	PEG-INF-α/RBV	48 wk	24w	SVR, NR
Tanaka Y, et al. (2009)	314	314 (Asians)	314 (1)	PEG-INF-α/RBV	48 wk	24w	SVR, VR, NR
Honda M, et al. (2009)	168	168 (Asians)	168 (1)	PEG-INF-α-2b/RVB	48 wk	24w	SVR, TR, NR, EVR
McCarthy JJ, et al. (2009)	231	178 (Caucasians)	186 (1)	NA	NA	24w	SVR, NR, Relapsers
McCarthy JJ, et al. (2009)	231	53 (Afro-Americans)	45 (2/3)	NA	NA	24w	SVR, NR, Relapsers
Rauch A, et al. (2009)	465	465 (Caucasians)	188 (1)	PEG-INF-α/RBV	48 wk	24w	SVR, NR
			222 (2/3)
			34 (4)
			21 (others)
Thompson AJ, et al. (2009)	1628	1287 (Caucasians)	1628 (1)	PEG-INF/RBV	48 wk	24w	SVR, EVR, RVR
		300 (Afro-Americans)
		41 (Others)